Blinatumomab is a medication that targets and removes specific B-cells (a type of white blood cell) from the immune system. It’s designed to help patients with autoimmune conditions where B-cells are causing inflammation and damage to the body’s tissues. This medication works by connecting toxic T-cells to harmful B-cells, leading to the destruction of these problematic B-cells. It’s given through an infusion into the bloodstream and is being studied as a potential treatment for several autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and granulomatous polyangiitis (GPA).

Systemic Lupus Erythematosus – A chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissues and organs. It can affect multiple parts of the body, including joints, skin, kidneys, blood cells, brain, heart, and lungs. The condition typically develops gradually, with periods of increased symptoms (flares) alternating with periods of mild or no symptoms (remission). Most people with lupus experience joint pain, skin rashes particularly on the face, and fatigue.

Systemic Sclerosis – A chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues. The condition causes an overproduction of collagen, which builds up in the skin and internal organs. It typically begins with Raynaud’s phenomenon, where fingers and toes change color in response to cold or stress. The skin gradually becomes thick and tight, particularly on the hands and face.

Granulomatosis with Polyangiitis – A rare autoimmune condition that causes inflammation of blood vessels in various parts of the body. The disease mainly affects the blood vessels in the nose, sinuses, throat, lungs, and kidneys. It develops when the immune system attacks healthy blood vessels, leading to the formation of inflammatory tissue masses called granulomas. Common early signs include persistent runny nose, nasal crusting, and sinus problems.